黄斑部病变治疗市场规模、份额、成长分析，按类型、按治疗方法、按疾病阶段、按给药途径、按地区 - 行业预测，2025-2032

2023 年全球黄斑部病变治疗市场规模价值 167 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.5%，从 2024 年的 181.2 亿美元增长至 2032 年的 181.2 亿美元。 348亿美元。

由于老龄化黄斑部病变（AMD）盛行率不断上升以及老年人口不断增加，全球黄斑部病变治疗市场正在快速发展。随着对有效治疗方案的需求不断增加，创新的抗 VEGF 疗法和缓释性药物传递系统等医学研究的重大进展正在改善患者的治疗效果。主要的市场趋势包括针对多种疾病途径的联合治疗的兴起和针对遗传因素的有前景的基因治疗方法。然而，挑战依然存在，包括高昂的治疗费用、有限的保险报销范围以及严格的监管要求。值得注意的是，亚太和拉丁美洲的新兴市场具有巨大的成长机会，人工智慧和机器学习技术的整合有望加强诊断和治疗，为个人化医疗铺平道路。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步

黄斑部病变治疗市场规模（按类型）

• 市场概况
• 干老龄化黄斑部病变
• 湿性老龄化黄斑部病变
• 其他的

黄斑部病变治疗市场规模（依治疗方法）

• 市场概况
• 抗内皮
• 其他的

黄斑部病变病变治疗市场规模（依疾病阶段）

• 市场概况
• 早期 AMD
• 中度 AMD
• 晚期 AMD

按给药途径分類的黄斑部病变治疗市场规模

• 市场概况
• 静脉注射
• 玻璃体内途径

黄斑部病变治疗市场规模（按分销管道）

• 市场概况
• 门诊手术中心
• 医院
• 其他管道

黄斑部病变治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Pfizer Inc.（United States）
• Regeneron Pharmaceuticals Inc.（United States）
• AbbVie Inc.（United States）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Bausch Health Companies Inc.（Canada）
• Amgen Inc.（United States）
• Biogen Inc.（United States）
• Samsung Bioepis（South Korea）
• PanOptica（United States）
• REGENXBIO Inc.（United States）
• Lineage Cell Therapeutics（United States）
• Ocugen Inc.（United States）
• Olix Pharmaceuticals Inc.（South Korea）
• ONL Therapeutics（United States）
• MeiraGTx（United States）
• OnPoint Vision Inc.（United States）
• Alcon（Switzerland）

结论和建议

Global Macular Degeneration Treatment Market size was valued at USD 16.7 billion in 2023 and is poised to grow from USD 18.12 billion in 2024 to USD 34.8 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

The global macular degeneration treatment market is rapidly evolving, driven by the increasing prevalence of age-related macular degeneration (AMD) and a rising elderly population. As the demand for effective therapeutic solutions grows, notable advancements in medical research, including innovative anti-VEGF therapies and sustained-release drug delivery systems, have improved patient outcomes. Key market trends highlight the rise of combination therapies, targeting multiple disease pathways, and promising gene therapy approaches that address genetic factors. However, challenges such as high treatment costs, limited reimbursement coverage, and stringent regulatory requirements persist. Notably, emerging markets in Asia-Pacific and Latin America present significant growth opportunities, while the integration of artificial intelligence and machine learning technologies promises to enhance diagnostics and treatment, paving the way for personalized medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macular Degeneration Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macular Degeneration Treatment Market Segmental Analysis

Global Macular Degeneration Treatment Market is segmented by Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration and Others. Based on Treatment, the market is segmented into Anti-vascular Endothelial and Others. Based on Stage of Disease, the market is segmented into Early-stage AMD, Intermediate AMD and Late-stage AMD. Based on Route of Administration, the market is segmented into Intravenous Route and Intravitreal Route. Based on Distribution Channel, the market is segmented into Ambulatory Surgical Centres, Hospitals and Other Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macular Degeneration Treatment Market

The macular degeneration treatment market is significantly influenced by the growing aging population. As macular degeneration predominantly impacts individuals over 50, the rise in the global elderly demographic is anticipated to escalate the incidence of this condition. The World Health Organization has projected that the population aged 60 and above will double by 2050. This demographic transformation is poised to enhance the demand for effective treatments targeting macular degeneration, driving market growth. Consequently, healthcare providers and pharmaceutical companies are increasingly focused on developing innovative therapies to address the needs of this expanding population segment, ultimately fostering advancements in treatment options.

Restraints in the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market faces several restraints, one of which is the stringent regulatory requirements that govern the industry. The process for obtaining approval for new treatment options is often protracted and can impose significant costs on pharmaceutical companies. This involves extensive clinical trials, rigorous safety assessments, and detailed regulatory submissions, all of which can hinder the timely introduction of novel therapies. Consequently, the intricate regulatory landscape may discourage some companies from investing in research and development for macular degeneration treatments, ultimately restricting the range and availability of innovative solutions for patients suffering from this condition.

Market Trends of the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market is increasingly influenced by the rise of telemedicine and remote monitoring technologies, which have revolutionized patient care in this sector. The shift towards these digital healthcare solutions facilitates remote assessments of vision and disease progression, minimizing the necessity for frequent in-person consultations. This trend not only enhances patient convenience and compliance but also enables timely interventions and effective disease management, ultimately driving down healthcare costs. Innovations such as home-based visual acuity testing and smartphone imaging devices are becoming integral in monitoring treatment efficacy and disease developments, underscoring a transformative move towards more accessible and efficient care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Macular Degeneration Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration
• Others

Global Macular Degeneration Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Anti-vascular Endothelial
• Others

Global Macular Degeneration Treatment Market Size by Stage of Disease & CAGR (2025-2032)

• Market Overview
• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

Global Macular Degeneration Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous Route
• Intravitreal Route

Global Macular Degeneration Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Ambulatory Surgical Centres
• Hospitals
• Other Channels

Global Macular Degeneration Treatment Market Size & CAGR (2025-2032)

• North America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PanOptica (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olix Pharmaceuticals Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ONL Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OnPoint Vision Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations